Despite Negative New York Times Article "Dubius Cardiac", Jefferies Maintains Buy on HCA Inc (HCA)

A DOJ inquiry and newly released New York Times article discussing "dubious cardiac" clinical and billing practices at HCA Inc (NYSE: HCA) has added a new overhang to this stock, thinks Arthur Henderson, an analyst at Jefferies.

"However, as prospects for another special dividend grow, these anxieties will abate, and the stock will likely move higher," said Henderson.

Jefferies has a Buy rating on HCA Holdings (NYSE: HCA). They firm lowered the price target to $30.00 (from $34.00) to reflect overhangs.

For an analyst ratings summary and ratings history on HCA Holdings click here. For more ratings news on HCA Holdings click here.

Shares of HCA Holdings closed at $25.55 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy